Compounded GLP-1s and Microdosing in 2026: What Actually Changed

For two years, cheap "compounded" versions of semaglutide and tirzepatide filled the gap left by brand shortages, and a whole culture of microdosing grew up around them. In 2026 that ground is shifting fast, because the shortage that made the copies legal has ended and regulators are closing the door. If you take a compounded GLP-1, or you are weighing one, here is what genuinely changed and what to watch.

In short

• The official shortage ended in 2025, and with it the clear legal basis for pharmacies to mass-produce copies of semaglutide and tirzepatide.
• Many compounders kept going by adding ingredients such as B vitamins and arguing the result is not "essentially a copy." Regulators dispute that.
• Microdosing, using smaller-than-label doses, became popular, but it rests on very little clinical evidence.
• Through 2026 the US regulator escalated enforcement: warning letters to telehealth sellers and moves to strip the drugs from bulk-compounding lists.
• Compounded is not automatically unsafe, but oversight and consistency vary. The approved brands and their active ingredient remain the benchmark.

Why were compounded GLP-1s ever allowed?

Because US law lets pharmacies compound copies of a drug only while it is in official shortage, and both semaglutide and tirzepatide spent 2023 and 2024 on the shortage list. Once a medicine comes off that list it counts as commercially available, and the permission to make near-copies falls away. Semaglutide left the shortage list in April 2025 and tirzepatide in March 2025, per the US Food and Drug Administration, which then set wind-down deadlines for pharmacies to stop.

So how is compounding still happening in 2026?

Two ways: through smaller state-level pharmacies that compound to an individual prescription, and through sellers who modify the formula to argue it is not a straight copy. By late 2025, more than 80 percent of compounded semaglutide and tirzepatide prescriptions included extra ingredients such as vitamin B6, B12 or levocarnitine, a formulation tweak used to claim the product is not "essentially a copy" of the brand. Regulators have not accepted that reasoning at face value, and through the first half of 2026 the FDA issued warning letters to telehealth companies over misleading claims and moved to remove the drugs from the list used for bulk compounding. The direction of travel is clear: the easy supply is narrowing.

Is microdosing GLP-1 a real strategy or a trend?

Microdosing, taking a fraction of the standard dose, is popular but not backed by the trial evidence that supports the approved doses. Around one in seven GLP-1 users were microdosing by late 2025. The idea is to capture appetite and metabolic benefits with fewer side effects and lower cost, and some people report it suits them. The honest position is that the large trials proving these drugs work for weight and blood sugar used the standard escalating doses, not micro ones, so microdosing is an experiment people are running on themselves rather than an evidence-based protocol. If you do it, do it with a clinician who can monitor you, not off a social media recipe.

Is compounded semaglutide safe?

It can be made well, but it is not held to the same manufacturing and testing standard as the approved brand, so quality and dose accuracy vary by source. The active ingredient can be genuine semaglutide, and many people used compounded versions without incident. The risks sit in the gaps: inconsistent concentration, added ingredients with their own effects, unclear sourcing, and sellers making claims that outrun the evidence. This is different from the generic-versus-brand question, where the generic is a fully approved product. A compound is made to order and is not reviewed the same way. If you use one, buy only through a legitimate pharmacy tied to a real prescription.

What are the alternatives worth knowing?

The approved GLP-1 medicines themselves, and for some people older options like metformin, remain the evidence-backed core. Brand semaglutide is the benchmark for both type 2 diabetes and obesity, and its evidence base is the one everything else is measured against. Metformin is a long-established, inexpensive option that a doctor may consider as part of a plan. And it is worth separating all of this from the supplement claims, the "natural Ozempic" pitches covered in our berberine reality check, which are a different and weaker category again. Browse the weight loss and diabetes pages for the medicines in context.

The bottom line

The compounded GLP-1 era is not over, but the wide-open version of it is closing as the shortage ends and enforcement tightens. Microdosing is a trend ahead of its evidence. None of that makes compounds automatically dangerous, but it does mean the safest ground is an approved medicine, a real prescription and a clinician watching the dose. Rules differ by country, so check what applies where you are.

This article is educational and does not replace advice from a doctor or pharmacist who knows your health history.